Bristol-Myers Squibb (BMY) Fundamental Analysis: Revenue, Earnings & Valuation

6.33 / 10

Outperform

BMY’s fundamentals earn an Outperform rating (6.3/10). Strengths include a low cost‑of‑sales ratio (28.9%), strong interest coverage (34.9), robust PB‑ROE (0.158) and positive Profit‑MV. Weaknesses are flat YoY revenue growth (‑0.22%). Overall, fundamentals are encouraging.

Analysis Checks(5/10)

Total operating revenue (YoY growth rate %)

Value-0.22

Score1/3

Weight-1.42%

1M Return-0.48%

Days sales outstanding

Value82.77

Score1/3

Weight-4.48%

1M Return-1.61%

Accounts receivable turnover ratio

Value4.35

Score3/3

Weight-3.19%

1M Return-1.06%

Profit-MV

Value1.34

Score3/3

Weight38.23%

1M Return9.28%

PB-ROE

Value0.16

Score3/3

Weight48.01%

1M Return12.21%

Income tax / Total profit (%)

Value24.36

Score0/3

Weight-5.93%

1M Return-2.17%

Interest coverage ratio (EBIT / Interest expense) (%)

Value34.93

Score2/3

Weight-3.60%

1M Return-1.25%

Operating revenue (YoY growth rate %)

Value-0.22

Score1/3

Weight-1.23%

1M Return-0.42%

Cost of sales ratio (%)

Value28.92

Score3/3

Weight3.89%

1M Return1.16%

Asset-MV

Value-0.55

Score1/3

Weight29.71%

1M Return6.70%

Is BMY undervalued or overvalued?

BMY scores 6.33/10 on fundamentals and holds a Discounted valuation at present. Backed by its 40.43% ROE, 14.64% net margin, 16.57 P/E ratio, 6.32 P/B ratio, and 178.68% earnings growth, these metrics solidify its Outperform investment rating.